NCT07113496View on ClinicalTrials.gov

RN1201injection for Relapsed/Refractory CD19+/BCMA+ Hematologic Malignancies

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

August 31, 2025

Primary Completion Date

August 31, 2027

Study Completion Date

December 31, 2027

Conditions
Relapsed or Refractory B-cell Hematologic MalignanciesB-cell Acute Lymphoblastic Leukemia (B-ALL)Multiple Myeloma (MM)Plasmablastic LymphomaRelapsed or Refractory CD19+/BCMA+ Hematologic MalignanciesMature B-Cell Lymphoma
Interventions
BIOLOGICAL

Allogeneic CAR-T

Patients will receive lymphodepletion chemotherapy followed by a single intravenous infusion of Allogeneic CAR-T cells. In select cases, CAR-T infusion may be administered post-autologous hematopoietic stem cell transplantation (auto-HSCT)

Trial Locations (1)

210029

The First Affiliated Hospital with Nanjing Medical University, Nanjing

All Listed Sponsors
lead

The First Affiliated Hospital with Nanjing Medical University

OTHER